Oncotype

Exact Sciences to participate in June investor conferences

Retrieved on: 
Monday, May 24, 2021

MADISON, Wis., May 24, 2021 /PRNewswire/ --Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

Key Points: 
  • MADISON, Wis., May 24, 2021 /PRNewswire/ --Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Retrieved on: 
Thursday, May 20, 2021

"Exact Sciences is changing the way we detect and treat cancer.

Key Points: 
  • "Exact Sciences is changing the way we detect and treat cancer.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Retrieved on: 
Wednesday, May 19, 2021

"Exact Sciences is changing the way we detect and treat cancer.

Key Points: 
  • "Exact Sciences is changing the way we detect and treat cancer.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.

Exact Sciences Announces First Quarter 2021 Results

Retrieved on: 
Tuesday, May 4, 2021

b'MADISON, Wis., May 4, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $402.1 million for the first quarter ended March31, 2021, compared to $347.8 million for the same period of 2020.\n"The first quarter demonstrated Exact Sciences is well-positioned for growth today and into the future," said Kevin Conroy, Chairman and CEO.

Key Points: 
  • b'MADISON, Wis., May 4, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $402.1 million for the first quarter ended March31, 2021, compared to $347.8 million for the same period of 2020.\n"The first quarter demonstrated Exact Sciences is well-positioned for growth today and into the future," said Kevin Conroy, Chairman and CEO.
  • ET to discuss first quarter 2021 results.
  • The Oncotype DX AR-V7 Nucleus Detect test is performed by Epic Sciences at its centralized, CLIA-certified laboratory in San Diego and offered exclusively by Exact Sciences.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.\nThis news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future.

Exact Sciences to participate in May investor conferences

Retrieved on: 
Monday, May 3, 2021

b"MADISON, Wis., May 3, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast.\nA leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.

Key Points: 
  • b"MADISON, Wis., May 3, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast.\nA leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.\n"

Exact Sciences schedules first quarter 2021 earnings call

Retrieved on: 
Thursday, April 8, 2021

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.

Key Points: 
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Exact Sciences schedules fourth quarter 2020 earnings call

Retrieved on: 
Monday, February 1, 2021

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.

Key Points: 
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Exact Sciences to participate in J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 28, 2020

MADISON, Wis., Dec. 28, 2020 /PRNewswire/ --Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.

Key Points: 
  • MADISON, Wis., Dec. 28, 2020 /PRNewswire/ --Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.
  • Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice

Retrieved on: 
Friday, December 11, 2020

These data highlight the role of the test in further individualizing treatment decisions in early breast cancer.

Key Points: 
  • These data highlight the role of the test in further individualizing treatment decisions in early breast cancer.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

Retrieved on: 
Wednesday, December 9, 2020

RxPONDER showed a different effect of chemotherapy based on Recurrence Score results for postmenopausal and premenopausal women.

Key Points: 
  • RxPONDER showed a different effect of chemotherapy based on Recurrence Score results for postmenopausal and premenopausal women.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.